Insider trade

Officer received an award of 50K UTHR derivative securities

Traded Mar 15, 2023 · Filed Feb 27, 2026

United TherapeuticsUTHR

50K
Derivative units

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Mar 15, 2023
Reporting period: Not applicable
Filed with the SEC: Feb 27, 2026

OfficerGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001231589-26-000005
Filed / recorded

Feb 27, 2026, 2:31 AM UTC

Added to OQRO

Oct 6, 2026, 9:34 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

UNITED THERAPEUTICS Corp

Issuer CIK

1082554

Ticker

UTHR

Reporting person

Paul A Mahon

Relationship

Officer

Officer title

EVP & GENERAL COUNSEL

Security

Stock Options

Table

Derivative (Table II)

Transaction date

Mar 15, 2023

Transaction code

A

Shares / units

49,860

Price per share

$0.00

Acquired / disposed

Acquired (A)

Shares owned after

49,860

Ownership form

Direct

Amendment

No

Footnotes from the filing

These performance-based stock options were initially awarded on March 15, 2023, subject to a three-year performance condition tied to average cash profit margin during 2023-2025, which was determined on February 25, 2026. The number of stock options reported represents the number of options earned based on performance, all of which will vest on March 15, 2026.

Around the same time

Martine A RothblattChairperson & CEO

Filed 6mo ago

9,500Shares · @ $146.03

Traded Mar 26 · filed 2 days later

Derivative exercise or conversion — not an open-market buy.

More Official record

Martine A Rothblatt (Chairperson & CEO) sold ~$84K of United Therapeutics

Scheduled in advanceFiled 6mo ago

Martine A Rothblatt (Chairperson & CEO) sold ~$447K of United Therapeutics

Scheduled in advanceFiled 6mo ago